



New Books from Gaskell

Affective and Non-Psychotic Disorders

Recent topics from *Advances in Psychiatric Treatment*, Volume 2

Edited by Alan Lee

New

This second volume of the series discusses the evidence-based assessment of deliberate self-harm, and covers the special problems of general psychiatric practice when alcohol misuse and severe personality disorder complicate the picture. There are comparisons of 'old' and 'new' antidepressants, and reviews of strategies for preventing relapse and recurrence, and managing resistant depression. There is helpful advice on the specific problems in managing obsessive-compulsive and eating disorders, in dealing with somatisation, and in providing support and treatment for the victims of severe trauma.

November 1999, £15.00, 160pp, Paperback,
ISBN 1 901242 17 X

Mental Health of Ethnic Minorities: An Annotated Bibliography

Dinesh Bhugra

New

This book provides a valuable tool in approaching this central strand in the research and practice of psychiatry. Dr Bhugra has collected the most important research published in this arena over the past two decades, and using over twenty years' experience as a cross-cultural psychiatrist has summarised each study in a concise and readable format. Introduced with an executive summary, this annotated bibliography will provide an essential resource for clinicians and researchers, mental health professionals involved in cross-cultural psychiatry, service planners and policy makers, as well as anyone needing guidance through the vast and sometimes confusing literature on mental health in minority ethnic groups.

October 1999, £10.00, 113pp, Paperback,
ISBN 1 901242 31 5

Improving the Care of Elderly People with Mental Health Problems: Clinical Audit Project Examples

Kirsty MacLean Steel and Claire Palmer

New

Clinical audit is an essential part of modern health care delivery. This book, developed by the Royal College of Psychiatrists' Research Unit, contains a selection of clinical audit projects within old age mental health services, all of which have been carried out in practice, with some still in progress. The projects have been divided into topic areas and formatted into structured abstracts for ease of use. The following professions will find this book an invaluable guide for use in everyday practice: old age psychiatrists, psychologists, clinical audit coordinators, nurses, quality and effectiveness staff

October 1999, £15.00, 65pp, Paperback,
ISBN 1 901242 38 2

Getting on with Epilepsy

Books Beyond Words series

Sheila Hollins, Jane Bernal and Alice Thacker
Illustrated by Lisa Kopper

New

Getting on with Epilepsy is aimed at adults with learning disabilities and their families. This book illustrates experiences that can be worrying for people with epilepsy such as having a seizure in public, going to the doctor, having a brain scan, an EEG, a blood test, and taking daily medication. The book also stimulates discussion about the balance between personal autonomy and the need for safety. Many specific safety issues, such as cycling, cooking, safe drinking and swimming are addressed, demonstrating that it is possible to enjoy an active and independent life with epilepsy.


October 1999, 96pp, £10.00,
ISBN 1 901242 39 0

Gaskell is the imprint of the Royal College of Psychiatrists. Gaskell books are available from good bookshops and from Book Sales, Royal College of Psychiatrists, 17 Belgrave Square, London SW1X 8PG. Telephone +44 (0)171 235 2351 extension 146, fax +44 (0)171 245 1231. Credit card orders can be taken over the telephone. The latest information on College publications can be seen on the Internet at www.rcpsych.ac.uk



Spot the Edronax difference.



 Highly selective noradrenaline re-uptake inhibitor (NARI)¹

 **Edronax**[®]
reboxetine tablets

Helps restore energy and motivation in tired depressed patients^{2,3}

EDRONAX © ABBREVIATED PRESCRIBING INFORMATION

Presentation: Tablets containing 4mg reboxetine. **Indications:** Use in the acute treatment of depressive illness, and maintenance of clinical benefit in patients responsive to treatment. **Posology and method of administration:** **Adults** 4 mg b.i.d. (8 mg/day) administered orally. After 3-4 weeks, can increase to 10 mg/day. **Elderly and children** Elderly patients have been studied in comparative clinical trials at doses of 2 mg b.i.d., although not in placebo controlled conditions. There is no experience in children and therefore reboxetine cannot be recommended in either of these groups. **Renal/Hepatic Insufficiency** 2 mg b.i.d. which can be increased based on patient

precautions for use: Close supervision is required for subjects with a history of convulsive disorders and must be discontinued if the patient develops seizures. Avoid concomitant use with MAO-inhibitors. Close supervision of bipolar patients is recommended. Close supervision should be applied in patients with current evidence of urinary retention, glaucoma, prostatic hypertrophy and cardiac disease. At doses higher than the maximum recommended, orthostatic hypotension has been observed with greater frequency. Particular attention should be paid when administering reboxetine with other drugs known to lower blood pressure. **Interactions with other medicaments and other forms of interaction:** Reboxetine should not be co-

that have a narrow therapeutic margin and are metabolised by CYP3A4 or CYP2D6 e.g. anti-arrhythmics (flecainide), anti-psychotic drugs and tricyclic anti-depressants. No pharmacokinetic interaction with lorazepam. Reboxetine does not appear to potentiate the effect of alcohol. **Pregnancy and lactation:** Reboxetine is contraindicated in pregnancy and lactation. **Effects on ability to drive and use machines:** Reboxetine is not sedative per se. However, as with all psychoactive drugs, caution patients about operating machinery and driving. **Undesirable effects:** Adverse events occurring more frequently than placebo are: dry mouth, constipation, insomnia, paraesthesia, increased sweating, tachycardia, vertigo, urinary hesitancy /retention, impotence. **Overdose:** Monitor

NHS Price: Pack of 60 tablets in blisters £19.80. **Legal Category:** POM **Marketing Authorisation Holder:** Pharmacia & Upjohn Limited, Davy Avenue, Milton Keynes, MK5 8PH, UK. **Marketing Authorisation Number:** PL 0032/0216 **References:** 1. Brunello N et al. *Human Psychopharmacology* 1998;13:S13-S19. 2. Dubini A et al. *J Psychopharmacol* 1997; 11(4):S17-S23. 3. Montgomery SA. *Prescriber* April 1998; 116-119. Further information is available from the Marketing Authorisation Holder: Pharmacia & Upjohn Limited, Davy Avenue, Knowlhill, Milton Keynes, MK5 8PH, UK. Telephone: 01908 661101. © Edronax is a registered trademark. Code No.P4008/12/98. Date of preparation: November 1998